What are the side effects of ruxolitinib tablets/Jiekewei?

Ruxolitinib tablets/ruxolitinib(JAKAVI), as an inhibitor targeting JAK1/2, has shown good efficacy in the treatment ofmyelofibrosis, polycythemia vera andGVHD. However, like most targeted drugs, ruxolitinib may also cause a series of side effects while working. Understanding these potential adverse reactions can help patients and doctors work together to develop reasonable treatment and monitoring plans.

First, hematology-related adverse reactions are common side effects of ruxolitinib. Because its mechanism of action involves inhibiting the JAK pathway, it may affect bone marrow hematopoietic function, leading to anemia, thrombocytopenia or leukopenia. Patients may experience fatigue, bleeding tendencies, or reduced ability to resist infection during long-term treatment. Therefore, doctors usually monitor blood levels regularly during medication and adjust the dose or take supportive care based on the results.

Secondly, the increased risk of infection is also a clinical concern. Due to suppression of immune regulatory pathways, some patients may develop herpes zoster, respiratory infections, or other opportunistic infections. Doctors often assess a patient's history of past infections before treatment and prescribe preventive medication or close monitoring if necessary.

In addition, some patients may experience metabolic side effects during medication, such as weight gain, dyslipidemia, or mild elevation of liver function indicators. These changes are usually related to the regulation of inflammatory factor levels by drugs. Although they are not serious in most cases, they still need to be reviewed regularly to ensure safety.

Some patients may also experience mild adverse reactions, such as headache, dizziness, gastrointestinal discomfort, or rash. Such symptoms can usually be relieved in the short term, but if they persist or seriously affect their lives, they should seek medical treatment in time.

Reference materials:https://www.jakavi.com/